UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 9 von 666
Datensatz exportieren als...
BibTeX
Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Clinical cancer research, 2013-11, Vol.19 (22), p.6305-6312
GAJJAR, Amar
STEWART, Clinton F
BOYETT, James M
GILBERTSON, Richard J
CURRAN, Tom
ELLISON, David W
KASTE, Sue
KUN, Larry E
PACKER, Roger J
GOLDMAN, Stewart
CHINTAGUMPALA, Murali
WALLACE, Dana
TAKEBE, Naoko
2013
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
GAJJAR, Amar
STEWART, Clinton F
BOYETT, James M
GILBERTSON, Richard J
CURRAN, Tom
ELLISON, David W
KASTE, Sue
KUN, Larry E
PACKER, Roger J
GOLDMAN, Stewart
CHINTAGUMPALA, Murali
WALLACE, Dana
TAKEBE, Naoko
Titel
Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Ist Teil von
Clinical cancer research, 2013-11, Vol.19 (22), p.6305-6312
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2013
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. Initially, vismodegib was administered daily at 85 mg/m(2) and escalated to 170 mg/m(2). The study was then revised to investigate a flat-dosing schedule of 150 mg for patients with small body surface area (BSA, 0.67-1.32 m(2)) or 300 mg for those who were larger (BSA, 1.33-2.20 m(2)). Pharmacokinetics were performed during the first course of therapy, and the right knees of all patients were imaged to monitor bone toxicity. Immunohistochemical analysis was done to identify patients with Sonic Hedgehog (SHH)-subtype medulloblastoma. Thirteen eligible patients were enrolled in the initial study: 6 received 85 mg/m(2) vismodegib, and 7 received 170 mg/m(2). Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level. Three dose-limiting toxicities were observed, but no drug-related bone toxicity was documented. The median (range) vismodegib penetration in the cerebrospinal fluid (CSF) was 0.53 (0.26-0.78), when expressed as a ratio of the concentration of vismodegib in the CSF to that of the unbound drug in plasma. Antitumor activity was seen in 1 of 3 patients with SHH-subtype disease whose tumors were evaluable, and in none of the patients in the other subgroups. Vismodegib was well tolerated in children with recurrent or refractory medulloblastoma; only two dose-limiting toxicities were observed with flat dosing. The recommended phase II study dose is 150 or 300 mg, depending on the patient's BSA. Clin Cancer Res; 19(22); 6305-12. ©2013 AACR.
Sprache
Englisch
Identifikatoren
ISSN: 1078-0432
eISSN: 1557-3265
DOI: 10.1158/1078-0432.CCR-13-1425
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3856244
Format
–
Schlagworte
Adolescent
,
Anilides - adverse effects
,
Anilides - pharmacokinetics
,
Anilides - therapeutic use
,
Antineoplastic agents
,
Antineoplastic Agents - adverse effects
,
Antineoplastic Agents - pharmacokinetics
,
Antineoplastic Agents - therapeutic use
,
Biological and medical sciences
,
Cerebellar Neoplasms - drug therapy
,
Child
,
Child, Preschool
,
Dose-Response Relationship, Drug
,
Female
,
Humans
,
Male
,
Maximum Tolerated Dose
,
Medical sciences
,
Medulloblastoma - drug therapy
,
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
,
Neurology
,
Pharmacology. Drug treatments
,
Pyridines - adverse effects
,
Pyridines - pharmacokinetics
,
Pyridines - therapeutic use
,
Receptors, G-Protein-Coupled - antagonists & inhibitors
,
Smoothened Receptor
,
Treatment Outcome
,
Tumors
,
Tumors of the nervous system. Phacomatoses
,
Young Adult
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX